ZYNE Zynerba Pharmaceuticals Inc.

8.47
+0.46  (+6%)
Previous Close 8.01
Open 8.88
Price To Book 3.73
Market Cap 149274204
Shares 17,623,873
Volume 1,934,766
Short Ratio 2.59
Av. Daily Volume 653,859

SEC filingsSee all SEC filings

  1. 8-K - Current report 181053905
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986726
  3. 8-K - Current report 18986568
  4. 8-K - Current report 18963179
  5. 424B5 - Prospectus [Rule 424(b)(5)] 18963162

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial failed to meet target blood levels. Company to focus on ZYN002.
ZYN001
Healthy volunteers
Development to be discontinued - noted January 2018.
ZYN001
Fibromyalgia
Development to be discontinued - noted January 2018.
ZYN001
Peripheral Neuropathic Pain (PNP)
Pivotal trial initiation announced July 9, 2018 with top-line data due 2H 2019.
ZYN002
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
ZYN002 - STOP
Osteoarthritis
Phase 2 data released August 7, 2017 - endpoints not met. Phase 2b trial to be initiated 2H 2018.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2 open label trial initiation announced April 10, 2018. Top-line data due 2019.
Phase 2 BELIEVE 1
Developmental and Epileptic Encephalopathies (DEE)

Latest News

  1. Cantor Fitzgerald's 7 Buys For 7 Biotechs
  2. Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
  3. CBD Stocks Set to Explode
  4. What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
  5. Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  6. Zynerba Pharmaceuticals Continues Its 3-Day Rally
  7. Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT
  8. The Worst-Performing Marijuana Stocks in July
  9. Zynerba: 2Q Earnings Snapshot
  10. Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
  11. Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
  12. Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
  13. This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up
  14. Market Roasts Shares of Zynerba Pharmaceuticals
  15. Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
  16. Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
  17. Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  18. Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2
  19. Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
  20. Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

SEC Filings

  1. 8-K - Current report 181053905
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986726
  3. 8-K - Current report 18986568
  4. 8-K - Current report 18963179
  5. 424B5 - Prospectus [Rule 424(b)(5)] 18963162
  6. 8-K - Current report 18960545
  7. 424B5 - Prospectus [Rule 424(b)(5)] 18960532
  8. 8-K - Current report 18949675
  9. 8-K - Current report 18943371
  10. 8-K - Current report 18939503